AstraZeneca invests $200 mln in new China factory
LONDON Oct 10 (Reuters) - AstraZeneca , Britain's second-largest drugmaker, is to invest $200 million in a new factory in China, representing the company's largest ever investment in a single manufacturing facility globally.
The unit will produce both intravenous and oral solid medicines for the company's growing business in China, AstraZeneca said on Monday. Construction is scheduled to be completed at the end of 2013.
AstraZeneca's turnover in China was more than $1 billion in 2010 and the group has made emerging markets, including China, a top priority for future growth.
The new factory will be located in China Medical City, Taizhou, Jiangsu province.
- First Ebola victim in Sierra Leone capital on the run
- Amazon's far-reaching ambitions, lack of profits, unnerve investors |
- Apple iPhones allow extraction of deep personal data, researcher finds
- Short Gaza truce takes hold; many bodies pulled from rubble |
- EU edges to economic sanctions on Russia but narrows scope |